Alumis swings to Q2 net loss of $142.2 million on $41.8 million impairment
Alumis reported a net loss of $142.2 million for the quarter ended June 30, 2026, compared with net income of $59.3 million a year earlier, which included a $187.9 million non-operating gain tied to its ACELYRIN merger. The company took a $41.8 million impairment on the lonigutamab program after deciding to explore strategic alternatives for it, and reaffirmed that its $502.3 million in cash and marketable securities should fund operations into the fourth quarter of 2027.
Key points
- Net loss of $142.2 million for the quarter, versus net income of $59.3 million a year earlier, which included a $187.9 million ACELYRIN merger gain.
- Collaboration revenue of $1.7 million, down from $2.7 million a year earlier.
- $41.8 million impairment loss on the acquired IPR&D intangible asset for the lonigutamab program.
- Cash, cash equivalents and marketable securities of $502.3 million as of June 30, 2026; NDA submission for envudeucitinib in psoriasis planned for Q4 2026.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.